Navigation Links
Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, presented poster presentations at the 5th International Society for Stem Cell Research Annual Meeting (ISSCR) in Cairns, Queensland, Australia from June 17-20 and at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia from June 24-27. The two presentations covered recent research from Opexa's innovative adult stem cell program regarding the development of adult monocyte-derived islets, as beta-cell replacement therapy for diabetes mellitus.

The first presentation was made by Opexa's director of stem cell research, Glenn Winnier, Ph.D. at the ISSCR Annual Meeting and described the differentiation of adult monocyte-derived stem cells (MDSCs) to generate pancreatic endocrine cell clusters known as monocyte-derived islets (MDIs). MDIs express pancreatic specific factors as well as hormones insulin, glucagons and somatostatin in physiological proportions. These studies also demonstrated that MDIs function in a glucose responsive manner when transplanted into diabetic animals. Study animals demonstrate a prolonged reduction (greater than 60 days) in blood glucose levels when MDIs were transplanted under the kidney capsule of stz-induced NOD/SCID mice.

The second presentation, also made by Dr. Winnier, was presented at the ISCT Annual Meeting in Sydney, Australia. The Company's recent adult stem cell research has demonstrated the successful generation of MDIs from insulin-dependent type 1 and type 2 diabetics. These insulin producing islet-like clusters express insulin, glucagon and somatostatin characteristic hormones found in pancreatic islets and function in a glucose responsive manner.

Dr. Winnier commented, "The development of adult MDIs from healthy subjects and the demonstration that these MDIs are functional in vitro and when transplanted into stz-induced NOD/SCID mice is a breakthrough for our adult stem cell program. The differentiation of MDIs derived from MDSCs produced from type 1 and type 2 diabetics is a major advance in the development of a cell replacement therapy for the treatment of diabetes."

"These presentations by Dr. Winnier demonstrate significant advancement of our stem cell development program and serve as proof-of-principle for our adult diabetes mellitus beta-cell replacement therapy development", said David McWilliams, chief executive officer. "The potential use of adult MDSCs for the development of functional MDIs maybe a viable alternative to the development of islet cells derived from embryonic stem cells."

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forwa rd-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Opexa Therapeutics, Inc.
Lynne Hohlfeld, 281-719-3421
lhohlfeld@opexatherapeutics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com


'"/>




Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Monitoring Patient Glucose Levels: New Advances in software make it easier
5. New Advances in Gastric Diagnostics: Smaller is Better
6. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
7. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
8. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
11. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI ... This is a new, greatly improved version of the Doctor Referral teaming dataset commonly ... Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by Medicare ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a new company ... Florida and Texas doctors' offices and clinics. This breakthrough testing is part of ... recognizes the role genes play in determining an individual's tolerance of and reaction ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived either ... in these patients. , But how often do ophthalmologists and optometrists in Sweden recommend ... risk of or with early symptoms of AMD? A study published recently ...
Breaking Medicine News(10 mins):